Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT01627054 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 7 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 |
| NCT03702231 | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) | completed | Phase 2 | 116 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00481091 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 60 | AbbVieINDUSTRY | 4 | Jun 13, 2023 | clinicaltrials |
| NCT00602459 | Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 2 | 418 | National Cancer Institute (NCI)NIH | 2 | May 22, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT01168921 | Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02802943 | iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL | completed | Phase 2 | 56 | University Hospital TuebingenOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT01455051 | Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation | completed | Phase 2 | 25 | Grupo Espanol de trasplantes hematopoyeticos y terapia celularOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03939234 | Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. | completed | Phase 2 | 19 | Lars Møller PedersenOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT01125176 | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL(ThRiL) | completed | Phase 2 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02983617 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 36 | Gilead SciencesINDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02639910 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi(COSMOS) | completed | Phase 2 | 24 | MorphoSys AGINDUSTRY | 6 | Dec 20, 2021 | clinicaltrials |
| NCT01889186 | A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion | completed | Phase 2 | 158 | AbbVieINDUSTRY | 7 | Dec 16, 2021 | clinicaltrials |
| NCT03068416 | CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy | completed | Phase 2 | 24 | Uppsala UniversityOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT03045328 | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | completed | Phase 2 | 22 | Steven E. CoutreOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT00759798 | Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 289 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | completed | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01444716 | Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT00792077 | A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT02424968 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 18 | Robert LowskyOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT00378534 | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | completed | Phase 2 | 116 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 79 | Aptevo TherapeuticsINDUSTRY | 5 | Jun 10, 2021 | clinicaltrials |
| NCT01716208 | Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma | completed | Phase 2 | 12 | Joseph TuscanoOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT01497496 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03041636 | Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01441882 | Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03076437 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | completed | Phase 1 / Phase 2 | 28 | Shenzhen Institute for Innovation and Translational MedicineOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03755947 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 3 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant(UCBT) | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01269385 | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 22 | Mayo ClinicOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT02689141 | Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) | completed | Phase 2 | 66 | German CLL Study GroupOTHER | 1 | Jun 11, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 8, 2023source: clinicaltrials